The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Degradation of Endogenous and Exogenous Gastric Inhibitory Polypeptide in Healthy and in Type 2 Diabetic Subjects as Revealed Using a New Assay for the Intact Peptide1
Open accessAbstract
Gastric inhibitory polypeptide (GIP) is susceptible to degradation, but only recently has dipeptidyl peptidase IV been identified as the enzyme responsible. Most RIAs recognize both intact GIP-(1-42) and the noninsulinotropic N-terminally truncated metabolite, GIP-(3-42), hampering measurement of plasma concentrations. The molecular nature of GIP was examined using high pressure liquid chromatography and a newly developed RIA specific for the intact N-terminus of human GIP. In healthy subjects after a mixed meal, intact GIP (N-terminal RIA) accounted for 37.0+/-2.5% of the total immunoreactivity determined by C-terminal assay. High pressure liquid chromatographic analysis of fasting samples by C-terminal assay revealed one major peak (73.8+/-2.9%) coeluting with GIP-(3-42). One hour postprandially, two major peaks were detected, corresponding to GIP-(3-42) and GIP-(1-42) (58.1+/-2.7% and 35.7+/-4.2%, respectively). GIP-(3-42) was not detected by N-terminal assay; the major peak coeluted with intact GIP (86.4+/-5.8% and 81.3+/-0.9%, 0 and 1 h, respectively). After iv infusion, intact GIP constituted 37.1+/-4.1% and 41.3+/-3.4% of the total immunoreactivity in healthy and type 2 diabetic subjects, respectively. The plasma t1/2 was shorter (P < 0.0001) when determined by N-terminal compared with C-terminal assay (7.3+/-1.0 vs. 16.8+/-1.6 and 5.2+/-0.6 vs. 12.9+/-0.9 min, healthy and diabetic subjects, respectively), and both t1/2 were shorter in the diabetic group (P < 0.05). We conclude that dipeptidyl peptidase IV is important in GIP metabolism in humans in vivo, and that an N-terminally directed assay is required for determination of plasma concentrations of biologically active GIP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationMENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Self-citationDeacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Self-citationNauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506
Self-citationElahi, D., McAloon-Dyke, M., Fukagawa, N. K., Meneilly, G. S., Sclater, A. L., Minaker, K. L., Habener, J. F., & Andersen, D. K. (1994) · Regulatory Peptides · doi:10.1016/0167-0115(94)90136-8 · Cited by 309
Deacon, C. F., Knudsen, L. B., Madsen, K., Wiberg, F. C., Jacobsen, O., & Holst, J. J. (1998) · Diabetologia · doi:10.1007/s001250050903 · Cited by 303
Self-citationGlucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig
Deacon, C. F., Pridal, L., Klarskov, L., Olesen, M., & Holst, J. J. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.3.e458 · Cited by 299
Self-citation
Cited by
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Lambeir, A.-M., Durinx, C., Scharpé, S., & De Meester, I. (2003) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/713609354 · Cited by 955
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Self-citationThe role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
GIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 614
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Mulvihill, E. E., & Drucker, D. J. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1035 · Cited by 609
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528
Self-citationT., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
Herman, G. A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrodter, A., Keymeulen, B., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1009 · Cited by 495
Self-citationVilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444
Incretins, insulin secretion and Type 2 diabetes mellitus
Vilsbøll, T., & Holst, J. J. (2004) · Diabetologia · doi:10.1007/s00125-004-1342-6 · Cited by 444
Self-citationVilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00111-3 · Cited by 430
Self-citationPhysiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Deacon, C. F. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00080 · Cited by 428
Self-citationMuscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
Theodorakis, M. J., Carlson, O., Michopoulos, S., Doyle, M. E., Juhaszova, M., Petraki, K., & Egan, J. M. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00326.2004 · Cited by 396
Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes
Drucker, D. J. (2007) · Diabetes Care · doi:10.2337/dc07-0228 · Cited by 367
Mari, A., Sallas, W. M., He, Y. L., Watson, C., Ligueros-Saylan, M., Dunning, B. E., Deacon, C. F., Holst, J. J., & Foley, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2460 · Cited by 361
Self-citationGLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine
Mortensen, K., Christensen, L. L., Holst, J. J., & Orskov, C. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00125-3 · Cited by 359
Self-citationVollmer, K., Holst, J. J., Baller, B., Ellrichmann, M., Nauck, M. A., Schmidt, W. E., & Meier, J. J. (2008) · Diabetes · doi:10.2337/db07-1124 · Cited by 356
Self-citationReduced Incretin Effect in Type 2 Diabetes
Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes · doi:10.2337/db07-0100 · Cited by 349
Self-citationMeier, J. J., Nauck, M. A., Kranz, D., Holst, J. J., Deacon, C. F., Gaeckler, D., Schmidt, W. E., & Gallwitz, B. (2004) · Diabetes · doi:10.2337/diabetes.53.3.654 · Cited by 334
Self-citationPospisilik, J. A., Martin, J., Doty, T., Ehses, J. A., Pamir, N., Lynn, F. C., Piteau, S., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.741 · Cited by 332
Falkén, Y., Hellström, P. M., Holst, J. J., & Näslund, E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2876 · Cited by 315
Self-citationMeier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314
Self-citationHansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J. J., Schuit, F., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1326 · Cited by 309
2-Oleoyl Glycerol Is a GPR119 Agonist and Signals GLP-1 Release in Humans
Hansen, K. B., Rosenkilde, M. M., Knop, F. K., Wellner, N., Diep, T. A., Rehfeld, J. F., Andersen, U. B., Holst, J. J., & Hansen, H. S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0647 · Cited by 297
Self-citationNauck, M. A. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 295
Self-citationGlucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
Self-citationVilcacundo, R., Martínez-Villaluenga, C., & Hernández-Ledesma, B. (2017) · Journal of Functional Foods · doi:10.1016/j.jff.2017.06.024 · Cited by 264
The incretin system in healthy humans: The role of GIP and GLP-1
Holst, J. J. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.014 · Cited by 248
Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus
Mannucci, E., Pala, L., Ciani, S., Bardini, G., Pezzatini, A., Sposato, I., Cremasco, F., Ognibene, A., & Rotella, C. M. (2005) · Diabetologia · doi:10.1007/s00125-005-1749-8 · Cited by 206
Mentis, N., Vardarli, I., Köthe, L. D., Holst, J. J., Deacon, C. F., Theodorakis, M., Meier, J. J., & Nauck, M. A. (2011) · Diabetes · doi:10.2337/db10-1332 · Cited by 197
Self-citationAsmar, M., Simonsen, L., Madsbad, S., Stallknecht, B., Holst, J. J., & Bülow, J. (2010) · Diabetes · doi:10.2337/db10-0098 · Cited by 184
“In addition, arterial blood was analyzed for GIP (12) From the (1)Department of Clinical Physiology/Nuclear Medicine, Bispebjerg Hospital, Copenhagen, Denmark; the (2)Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; and the (3)Department of Endocrinology, Hvidovre Hospital, Hvidovre, D…”
MethodSelf-citationEdholm, T., Degerblad, M., Grybäck, P., Hilsted, L., Holst, J. J., Jacobsson, H., Efendic, S., Schmidt, P. T., & Hellström, P. M. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01554.x · Cited by 164
Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes
Nauck, M. A., Baller, B., & Meier, J. J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s190 · Cited by 163
Self-citationSecretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes
Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetes Care · doi:10.2337/dc13-0465 · Cited by 158
Self-citationMolecular mechanisms underlying nutrient-stimulated incretin secretion
Parker, H. E., Reimann, F., & Gribble, F. M. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s146239940900132x · Cited by 155
Rosenstock, J., Foley, J. E., Rendell, M., Landin-Olsson, M., Holst, J. J., Deacon, C. F., Rochotte, E., & Baron, M. A. (2008) · Diabetes Care · doi:10.2337/dc07-1616 · Cited by 153
Self-citationMeier, J. J., Kemmeries, G., Holst, J. J., & Nauck, M. A. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2212 · Cited by 146
Nauck, M. A., El-Ouaghlidi, A., Gabrys, B., Hücking, K., Holst, J. J., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Meier, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.020 · Cited by 137
Self-citationKielgast, U., Holst, J. J., & Madsbad, S. (2011) · Diabetes · doi:10.2337/db10-1790 · Cited by 137
Self-citationGastric inhibitory polypeptide does not inhibit gastric emptying in humans
Meier, J. J., Goetze, O., Anstipp, J., Hagemann, D., Holst, J. J., Schmidt, W. E., Gallwitz, B., & Nauck, M. A. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00499.2003 · Cited by 126
Self-citationNørregaard, P. K., Deryabina, M. A., Tofteng Shelton, P., Fog, J. U., Daugaard, J. R., Eriksson, P., Larsen, L. F., & Jessen, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13034 · Cited by 116
Lindgren, O., Mari, A., Deacon, C. F., Carr, R. D., Winzell, M. S., Vikman, J., & Ahrén, B. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0366 · Cited by 111
Self-citationSuccessful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36
Iepsen, E. W., Lundgren, J., Holst, J. J., Madsbad, S., & Torekov, S. S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1116 · Cited by 101
Self-citationIncretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Højberg, P. V., Zander, M., Vilsbøll, T., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetologia · doi:10.1007/s00125-008-0943-x · Cited by 89
Self-citationGlucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85
The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
Thondam, S. K., Daousi, C., Wilding, J. P. H., Holst, J. J., Ameen, G. I., Yang, C., Whitmore, C., Mora, S., & Cuthbertson, D. J. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00347.2016 · Cited by 71
Self-citationGlucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170174 · Cited by 67
Asmar, M., Simonsen, L., Asmar, A., Holst, J. J., Dela, F., & Bülow, J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1933 · Cited by 61
Self-citationMechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes
Horowitz, M., Rayner, C. K., & Jones, K. L. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0009-4 · Cited by 58
Chatterjee, D. J., Khutoryansky, N., Zdravkovic, M., Sprenger, C. R., & Litwin, J. S. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009339189 · Cited by 54
Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment
Neumiller, J. J. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.024 · Cited by 47
Delayed β-cell response and glucose intolerance in young women with Turner syndrome
Hjerrild, B. E., Holst, J. J., Juhl, C. B., Christiansen, J. S., Schmitz, O., & Gravholt, C. H. (2011) · BMC Endocrine Disorders · doi:10.1186/1472-6823-11-6 · Cited by 45
“Epinephrine and norepinephrine were measured by HPLC [17], glucagon by an in-house radioimmunoassay, GLP-1 by a Cterminal radioimmunoassay [18] and total GIP as previously described [19].”
MethodSelf-citationLiu, T., Ji, R.-L., & Tao, Y.-X. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108044 · Cited by 34
Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors
Deacon, C. F. (2020) · Peptides · doi:10.1016/j.peptides.2019.170196 · Cited by 31
Self-citationvan Raalte, D. H., Diamant, M., Ouwens, D. M., Ijzerman, R. G., Linssen, M. M. L., Guigas, B., Eringa, E. C., & Serné, E. H. (2013) · Diabetologia · doi:10.1007/s00125-013-3016-8 · Cited by 33
Irwin, N., Gault, V. A., O’Harte, F. P. M., & Flatt, P. R. (2020) · Peptides · doi:10.1016/j.peptides.2019.170203 · Cited by 27
GLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action
Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26
Holst, J. J. (2021) · Diabetes · doi:10.2337/dbi21-0026 · Cited by 23
“Our current hypothesis is that the processing of proglucagon in the pancreas is not 100% specific and that a minor fraction of proglucagon actually is processed to GLP-1(7-36)-amide (in humans, amidation of GLP-1 seems to be rather extensive) (22).”
BackgroundResultInfluentialEndurance Training Improves GLP-1 Sensitivity and Glucose Tolerance in Overweight Women
Åkerström, T., Stolpe, M. N., Widmer, R., Dejgaard, T. F., Højberg, J. M., Møller, K., Hansen, J. S., Trinh, B., Holst, J. J., Thomsen, C., et al. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac111 · Cited by 15
Self-citation
Metadata
- Authors
- Deacon, C. F., Nauck, M. A., Meier, J., Hücking, K., & Holst, J. J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-10
- Volume
- 85
- Issue
- 10
- Pages
- 3575-3581
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2079644358
- Cited by
- 401
- References
- 31
- FWCI
- 9.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.